Applications of the genO‑panhCD3/hPD-1 mouse model

Useful applications for researchers working on different biomedical fields, such as immuno-oncology, immuno-inflammation and autoimmunity:

  • Assess the efficacy of diverse compounds such as:

    • T-cell engagers targeting both hCD3 and hPD-1
    • Therapeutics targeting hPD-1, such as bispecific antibodies and immune checkpoint inhibitors
  • Evaluate the safety of therapeutics, such as inducing cytokine release syndrome (CRS) via treatment with hCD3-targeting antibodies
  • Gain insights into the mechanism of action (MOA) of diverse constructs and their potential therapeutic benefits

Features

  • Physiological expression of human CD3 and human PD-1
  • Functional CD3/TCR interaction
  • Functional T/B cell cooperation
  • Fully functional, and with unchanged homeostasis, mouse immune system
  • Lack of expression of the murine target genes

Guide: Compare CD3 mouse models for T-cell engager efficacy and safety studies. Read the guide →

Clients

No items found.

Customize this model

Tailor this model to meet your research needs:

  • Assess the efficacy and safety of therapeutics with multiple humanized targets
  • Simultaneously evaluate efficacy, safety, and PK in a single model
  • Assess the impact of the human Fc-domain of an antibody while assessing its efficacy and safety
  • Increase tolerance to human IgG1

…and more to fit your program

Model Delivery & Care

  • Read our FAQ on delivery & care here
  • Orders are made directly with genOway; breeding, housing and delivery are outsourced
  • Breeding facilities in the US and Europe through our trusted partners:
  • Quick, compliant, and reliable door-to-door delivery worldwide
  • Models with certified SOPF health status from AAALAC-accredited and PHS-assured professional breeders

Baseline validation

  • Extended validation

  • Extended validation

Discover related products to

genO-panhCD3/hPD-1

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
T-cell engager
CD3

genO-hCD3ε

genO‑hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

CD3
CD28
T-cell engager

genO-hCD3ε/hCD28

genO‑hCD3ε/hCD28 immunocompetent mice enable the efficacy assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

PD-1
Immune checkpoint
ICP (single-target)

genO-hPD-1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

genO-hPD-1/hCTLA-4

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

genO-hPD-1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
PD-1
ICP (multi-target)
Icos

genO-hPD-1/hICOS

The genO‑hPD‑1/hICOS mouse enables the in vivo efficacy assessment of compounds targeting the human immune checkpoint PD-1 and/or ICOS in fully immunocompetent mice.

Immune checkpoint
PD-1
Lag3
ICP (multi-target)

genO-hPD-1/hLAG3

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)

genO-hPD-1/hPD-L1

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)

genO-hPD-1/hTIM3

The genO‑hPD‑1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)

genO-hPD-1/hVISTA

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

T-cell engager
CD3

genO-panhCD3

genO‑panhCD3 (humanized ε, δ and γ chains - hCD3edg) immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

CD3
T-cell engager
Immune checkpoint
CD137

genO-panhCD3/hCD137

Double-humanized genO-panhCD3/hCD28 immunocompetent mice enable the efficacy assessment of anti-CD3 and CD137 compounds.

CD3
CD28
T-cell engager
Immune checkpoint

genO-panhCD3/hCD28

Double-humanized genO-panhCD3/hCD28 immunocompetent mice enable the efficacy assessment of anti-CD3 and CD28 compounds.

PD-L1
Immune checkpoint
MC38
PD-1

genO-MC38-hPD-L1-LZ

The genO-MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

Preclinical Double-Humanized genO-panhCD3/hPD-1 Mouse Model

Get in touch about

Let us know how we can help

Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe